EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, sofosbuvir 200 mg/velpatasvir 50 mg tablets) is indicated for the treatment of patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.

Please see below for Important Safety Information for EPCLUSA.

Many HCV patients are covered for EPCLUSA with
few restrictions

HCV patients who are Medicare/Medicaid dual-eligible may be able to get EPCLUSA
covered through their Medicare benefit

Find out about coverage for your patients

Coverage Results

Formulary information is provided by Fingertip Formulary® and is current as of 7/22/2020. Because formularies do change and many health plans offer more than one formulary, please check with the health plan directly to confirm coverage for individual patients.


Click here for patient support information, which may assist in identifying coverage options for your patients. The references to company/plan names listed do not, in any manner, imply an endorsement of EPCLUSA or any other products by the referenced companies/plans. Placement on the formulary is not intended to imply any claims regarding safety or efficacy of the products referenced.

See Access and Support

$5 Co-Pay Coupon

Help patients register for a co-pay coupon. Commercial patients may pay as little as $15 for a full course of EPCLUSA

Visit the EPCLUSA patient website to learn more

Check Your Patients' Eligibility

Commercial patients may pay as little as $5 per co-pay for their medicine. Patients are not eligible if they are enrolled in a government healthcare prescription drug program such as Medicare Part D or Medicaid (including patients who are in the Medicare coverage gap known as the “donut hole”).

The EPCLUSA Co-pay Coupon Program will cover the out-of-pocket costs for EPCLUSA prescriptions up to a maximum of 25% of the catalog price of a 12-week regimen of EPCLUSA.

EPCLUSA $5 Co-pay Coupon

Commercial patients may pay as little as $5 per co-pay for their medicine. Patients are not eligible if they are enrolled in a government healthcare prescription drug program such as Medicare Part D or Medicaid (including patients who are in the Medicare coverage gap known as the “donut hole”).

The EPCLUSA Co-pay Coupon Program will cover the out-of-pocket costs for EPCLUSA prescriptions up to a maximum of 25% of the catalog price of a 12-week regimen of EPCLUSA.

Have a patient starting treatment? Support Path® is here to help

Our team of Support Path Program Navigators can provide coverage information and financial support options that can help get patients started on Gilead treatments.

Talk with Support Path:

1-855-7-MYPATH (1-855-769-7284)

Visit MySupportPath.com
Support path is a program that can help patients get started on Gilead treatments
See Efficacy Data
See Dosing

Important Safety Information

BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

INDICATION

EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, sofosbuvir 200 mg/velpatasvir 50 mg tablets) is indicated for the treatment of patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.

Contraindications

  • If EPCLUSA is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information.

Warnings and Precautions

  • Serious Symptomatic Bradycardia when Coadministered with Amiodarone: Amiodarone is not recommended for use with EPCLUSA due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and or with advanced liver disease. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir-containing regimen. In patients without alternative viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
  • Risk of Reduced Therapeutic Effect Due to Concomitant Use of EPCLUSA with P-gp Inducers and/or Moderate to Strong Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with EPCLUSA as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.

Adverse Reactions

  • The most common adverse reactions (≥10%, all grades) with EPCLUSA were headache and fatigue; and when used with RBV in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Drug Interactions

  • Coadministration of EPCLUSA is not recommended with topotecan due to increased concentrations of topotecan.
  • Coadministration of EPCLUSA is not recommended with proton-pump inhibitors, phenobarbital, phenytoin, rifabutin, rifapentine, efavirenz, and tipranavir/ritonavir due to decreased concentrations of sofosbuvir and/or velpatasvir.

Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.


Please see full Prescribing Information for EPCLUSA, including BOXED WARNING.

VIEW ALL

Important Safety Information

BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION: IN HCV/HBV COINFECTED PATIENTS Test all patients for evidence of current or prior hepatitis B virus (HBV)... infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

INDICATION

EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, sofosbuvir 200 mg/velpatasvir 50 mg tablets) is indicated for the treatment of patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.

References:

  1. Data on file. Gilead Hepatitis C virus coverage status report. August 2020.
  2. Data on file. Data for SOF claims from December 2013 through June 2020.